Hormonal
GLP-1 receptor agonists (GLP-1RAs) induce significant weight loss in adults with obesity or overweight by acting on the central nervous system to increase satiety and on the gastrointestinal tract to delay gastric emptying.
GLP-1 medications (like Semaglutide or Tirzepatide) are highly effective for weight loss, often achieving 15-25% body weight reduction in clinical trials. They work by reducing appetite and slowing digestion. These are prescription medications, not supplements. They require long-term use to maintain weight loss, as stopping often leads to regain. They are generally safe but can cause gastrointestinal side effects. Consult a doctor to see if you are a candidate.
GLP-1RA 的减重机制包括:(1) 作用于中枢,抑制食欲,增加下丘脑弓状核饱食信号的水平,并降低抑制信号,从而增强饱腹感,减少热量摄入;(2) 作用于胃肠道,延缓胃排空和胃肠蠕动,减少胃泌素刺激的胃酸分泌。
Why this rating
The paper cites multiple large-scale, randomized, double-blind, placebo-controlled clinical trials (e.g., STEP 1, SURMOUNT-1) with significant sample sizes.
Source
The glucagon-like peptide-1 (GLP-1) drugs poised to conquer obesity
Jun Yin et al. · Chinese Science Bulletin (Chinese Version) · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →